Cutaneous angiosarcoma: own experience over 13 years. Clinical features, disease course and immunohistochemical profile

被引:37
作者
Donghi, D. [1 ]
Kerl, K. [1 ]
Dummer, R. [1 ]
Schoenewolf, N. [1 ]
Cozzio, A. [1 ]
机构
[1] Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland
关键词
clinical features; cutaneous angiosarcoma; immunohistochemistry; survival; KAPOSIS-SARCOMA; MARKER; SUBSET;
D O I
10.1111/j.1468-3083.2010.03624.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100227 [皮肤病学];
摘要
Background Cutaneous angiosarcoma (AS) is a rare malignant tumour of endothelial origin with very poor prognosis, frequent recurrences and high metastatic potential. Clinical suspicion is often raised too late, but histological findings and immunohistochemical assays have proved to be very helpful in the diagnostic process. Patients and methods Over the last 13 years, nine patients with AS were found in our archives. Clinical features, evolution, treatment and outcome were analysed and all biopsy specimens were reviewed by a trained dermatopathologist, with subsequent immunohistochemical assessment. Results and conclusions Cutaneous AS was clinically diagnosed in 4 of 9 patients, while systemic lupus erythematosus was the most common misdiagnosis. Radiotherapy was the most prescribed treatment, but many different combinations of surgery, chemotherapy and radiotherapy were observed. Mean disease-free and overall survival (15.4 and 23.7 respectively) were consistent with previous series, with local recurrence rate (2/9) lower than previously reported data. CD31 was positive in all patients. Vimentin, D2-40 and VEGFR-3 were expressed by the vast majority, Factor VIII by 3/7 and CD34 by about 1/3 of patients. Cytokeratin was negative in all patients. The patients with the most unfavourable course showed a strong expression of Ki-67, while those with the best outcome only had a slight positive Ki-67 staining. Larger studies regarding tumour cell expression of Ki-67 and other markers such as D2-40 will be helpful to evaluate a potential prognostic value of these stainings.
引用
收藏
页码:1230 / 1234
页数:5
相关论文
共 18 条
[1]
Treatment and outcome of 82 patients with angiosarcoma [J].
Abraham, John A. ;
Hornicek, Francis J. ;
Kaufman, Adam M. ;
Harmon, David C. ;
Springfield, Dempsey S. ;
Raskin, Kevin A. ;
Mankin, Henry J. ;
Kirsch, David G. ;
Rosenberg, Andrew E. ;
Nielsen, G. Petur ;
Desphpande, Vikram ;
Suit, Herman D. ;
DeLancy, Thomas F. ;
Yoon, Sam S. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (06) :1953-1967
[2]
Al-Abbadi MA, 2007, ARCH PATHOL LAB MED, V131, P288
[3]
Cutaneous angiosarcoma of the face [J].
Cannavò, SP ;
Lentini, M ;
Magliolo, E ;
Guarneri, C .
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2003, 17 (05) :594-595
[4]
Cutaneous angiosarcomas [J].
Fink-Puches, R ;
Smolle, J ;
Beham, A ;
Kerl, H ;
Soyer, HP .
HAUTARZT, 2000, 51 (07) :479-485
[5]
Vascular endothelial growth factor receptor-3 (VEGFR-3): A marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas [J].
Folpe, AL ;
Veikkola, T ;
Valtola, R ;
Weiss, SW .
MODERN PATHOLOGY, 2000, 13 (02) :180-185
[6]
Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's sarcoma and a subset of angiosarcomas [J].
Kahn, HJ ;
Bailey, D ;
Marks, A .
MODERN PATHOLOGY, 2002, 15 (04) :434-440
[7]
MADDOX JC, 1981, CANCER-AM CANCER SOC, V48, P1907, DOI 10.1002/1097-0142(19811015)48:8<1907::AID-CNCR2820480832>3.0.CO
[8]
2-T
[9]
Cutaneous angiosarcoma [J].
Mendenhall, William M. ;
Mendenhall, Charles M. ;
Werning, John W. ;
Reith, John D. ;
Mendenhall, Nancy P. .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2006, 29 (05) :524-528
[10]
Cutaneous angiosarcoma: A case series with prognostic correlation [J].
Morgan, MB ;
Swann, M ;
Somach, S ;
Eng, W ;
Smoller, B .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 50 (06) :867-874